UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Supply and demand for hemophilia treatments—Systems-based approaches to mitigate the risk

Transfusion and apheresis science, 2018-12, Vol.57 (6), p.731-734

2018

Volltextzugriff (PDF)

Successful immune tolerance induction with von Willebrand factor containing concentrate in an adult with haemophilia A and chronic inhibitor - a case study

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-03, Vol.22 (2), p.e104-e106

2016

Volltextzugriff (PDF)

Home management of haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-03, Vol.10 (2), p.118-133

2004

Volltextzugriff (PDF)

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-11, Vol.20 (6), p.771-776

2014

Volltextzugriff (PDF)

The Jamaican Haemophilia Registry: Describing the burden of disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e179-e186

2018

Volltextzugriff (PDF)

Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-03, Vol.23 (2), p.e162-e165

2017

Volltextzugriff (PDF)

Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e401-e405

2016

Volltextzugriff (PDF)

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-05, Vol.13 (3), p.256-263

2007

Volltextzugriff (PDF)

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

The New England journal of medicine, 2017-12, Vol.377 (23), p.2215-2227

2017

Volltextzugriff (PDF)

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.227-239

2009

Volltextzugriff (PDF)

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.e251-e259

2014

Volltextzugriff (PDF)

A regional redistribution programme for the optimal management of clotting factor concentrates prescribed by haemophilia treatment centres

Transfusion medicine (Oxford, England), 2013-10, Vol.23 (5), p.370-372

2013

Volltextzugriff (PDF)

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-03, Vol.14 (2), p.281-286

2008

Volltextzugriff (PDF)

A Canadian survey of self-infusion practices in persons with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-11, Vol.18 (6), p.e403-e405

2012

Volltextzugriff (PDF)

Low prevalence of inhibitor antibodies in the Canadian haemophilia population

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-05, Vol.18 (3), p.e254-e259

2012

Volltextzugriff (PDF)

Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A

Thrombosis and haemostasis, 2000-03, Vol.83 (3), p.387-391

2000

Volltextzugriff (PDF)

Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis

Circulation (New York, N.Y.), 1999-10, Vol.100 (15), p.1616-1622

1999

Volltextzugriff (PDF)

A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-05, Vol.17 (3), p.516-521

2011

Volltextzugriff (PDF)

Viral safety of haemophilia treatment products

Annals of medicine (Helsinki), 2000-10, Vol.32 (7), p.485-492

Teitel, Jerome M

2000

Volltextzugriff (PDF)

Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study

The American heart journal, 2000-08, Vol.140 (2), p.272-278

2000

Volltextzugriff (PDF)

Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT

Haemophilia : the official journal of the World Federation of Hemophilia, 2006-01, Vol.12 (1), p.1-6

2006

Volltextzugriff (PDF)

Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique

Haemophilia : the official journal of the World Federation of Hemophilia, 2002-03, Vol.8 (2), p.112-120

2002

Volltextzugriff (PDF)

Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet

European journal of clinical nutrition, 2007-04, Vol.61 (4), p.483-492

2007

Volltextzugriff (PDF)

The safety of recombinant factor VIIa: a rebuttal

Journal of thrombosis and haemostasis, 2004-11, Vol.2 (11), p.2078-2078

2004

Volltextzugriff (PDF)

Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations

Haemophilia : the official journal of the World Federation of Hemophilia, 1999-09, Vol.5 (s3), p.43-49

Teitel, J M

1999

Volltextzugriff (PDF)

1 – 25 von 363

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(306)
Mit Volltextzugriff
(247)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(227)
Life Sciences & Biomedicine
(197)
Humans
(110)
Biological And Medical Sciences
(85)
Medical Sciences
(64)
Hematology
(56)
Male
(46)
Animals
(45)
Female
(43)
Agriculture
(42)
Cardiovascular System & Cardiology
(41)
Horticulture
(34)
Adult
(28)
Physical Sciences
(28)
Cardiac & Cardiovascular Systems
(27)
Greenhouses
(24)
Fundamental And Applied Biological Sciences. Psychology
(23)
Middle Aged
(22)
Hemophilia A - Drug Therapy
(21)
Peripheral Vascular Disease
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Supply and demand for hemophilia treatments—Systems-based approaches to mitigate the risk

Successful immune tolerance induction with von Willebrand factor containing concentrate in an adult with haemophilia A and chronic inhibitor - a case study

Home management of haemophilia

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010

The Jamaican Haemophilia Registry: Describing the burden of disease

Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study

Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System

A regional redistribution programme for the optimal management of clotting factor concentrates prescribed by haemophilia treatment centres

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

A Canadian survey of self-infusion practices in persons with haemophilia A

Low prevalence of inhibitor antibodies in the Canadian haemophilia population

Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A

Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis

A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients

Viral safety of haemophilia treatment products

Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study

Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT

Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique

Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet

The safety of recombinant factor VIIa: a rebuttal

Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations

Suchergebnisse filtern